Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

High Sensitivity for Detection of Primary Diagnostic Variants in Autism Spectrum Disorder, Including De Novo Variants, with Trio Whole Genome Sequencing and Data Reanalysis

Version 1 : Received: 9 August 2023 / Approved: 14 August 2023 / Online: 14 August 2023 (09:36:37 CEST)
Version 2 : Received: 29 September 2023 / Approved: 9 October 2023 / Online: 10 October 2023 (05:00:59 CEST)

How to cite: Bar, O.; Vahey, E.; Mintz, M.; Frye, R.E.; Boles, R.G. High Sensitivity for Detection of Primary Diagnostic Variants in Autism Spectrum Disorder, Including De Novo Variants, with Trio Whole Genome Sequencing and Data Reanalysis. Preprints 2023, 2023081002. https://doi.org/10.20944/preprints202308.1002.v2 Bar, O.; Vahey, E.; Mintz, M.; Frye, R.E.; Boles, R.G. High Sensitivity for Detection of Primary Diagnostic Variants in Autism Spectrum Disorder, Including De Novo Variants, with Trio Whole Genome Sequencing and Data Reanalysis. Preprints 2023, 2023081002. https://doi.org/10.20944/preprints202308.1002.v2

Abstract

Autism spectrum disorder (ASD) is a common condition with lifelong implications and a strong hereditary component suggesting genetic underpinnings. The last decade has seen dramatic improvements in DNA sequencing and related bioinformatics and databases. We analyzed the raw DNA sequencing files on the Variantyx® bioinformatics platform for the last 50 ASD patients evaluated with trio whole genome sequencing (trio-WGS). “Qualified” variants were defined as coding, rare, and evolutionarily conserved. Primary Diagnostic Variants (PDV) additionally were in genes directly linked to ASD and matched clinical correlation. A PDV was identified in 34/50 (68%) of cases, including 25 (50%) cases with heterozygous de novo and 10 (20%) with inherited variants. De novo variants in genes directly associated with ASD were far more likely to be Qualifying than non-Qualifying versus a control group of genes not associated with ASD (P = 0.0002, odds ratio 29), validating that most are indeed disease related. Only 14/34 (41%) of PDV cases had the variant listed on the laboratory report, and reanalysis increased diagnostic yield from 28% to 68%. Variants that we assigned as PDVs yet not on the report were predominately de novo in genes not yet reported as ASD associated. Many subjects both with and without a PDV had inherited Qualifying variants in known ASD-associated genes, suggesting polygenic inheritance. Thirty-three subjects (66%) had treatment recommendation(s) based on DNA analyses. Our results demonstrate high yield of trio-WGS for revealing molecular diagnoses in ASD that is greatly enhanced by re-analyzing DNA sequencing files. In contrast to previous reports, de novo variants dominate the findings, mostly representing novel conditions. This has implications to the cause and rising prevalence of autism.

Keywords

autism; diagnostic yield; DNA sequencing; novel disorders

Subject

Medicine and Pharmacology, Pediatrics, Perinatology and Child Health

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.